Dr Raj Singh previews key ASTRO 2026 data, from FMISO PET-guided de-escalation in HPV-positive head and neck cancer to SRS vs whole brain radiotherapy trials in brain metastases.
Commentary|Podcasts|May 20, 2026
ASCO 2026 Preview: Late-Breaking Abstracts Poised to Reshape the Treatment Landscape
Author(s)Sabrina Serani
Advertisement
Ahead of the 2026 ASCO Annual Meeting, Sabrina Serani, managing editor of Targeted Oncology, previews the late-breaking abstracts most likely to influence clinical practice across breast, colorectal, prostate, and lung cancer, as well as in metastatic uveal melanoma, a disease that has gone without an effective systemic therapy for decades. From VIKTORIA-1 in PIK3CA-mutant metastatic breast cancer to BREAKWATER's first look at overall survival in BRAF V600E-mutant colorectal cancer, this episode breaks down the science, the clinical context, and the questions that full data will need to answer.
Advertisement
Related to this article
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC
2
Behind the FDA Approval: Rusfertide Redefines the Polycythemia Vera Paradigm
3
Extended Survival Raises New Questions on Imaging and Treatment Intensification in ROS1+ NSCLC
4
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
5